Cellular and gene therapies have been hot topics for the past few years, with the medical community celebrating their advancements, and the healthcare community struggling with how to bring these advancements to patients. As the pipeline of new treatments continues to grow, BCS Chief Actuary Mehb Khoja recently shared his thoughts with Forbes about the benefits and challenges these therapies are bringing to the healthcare industry.
Read the article here.